Table 1 Patient characteristics

Female

39 (55.71)

17 (56.67)

12 (60.00)

10 (50.00)

0.811

Age, years

51.50 (45.23-61.23)

49.25 (41.83-59.12)

50.15 (45.17-61.95)

56.80 (51.35-62.38)

0.133

Disease duration, years

4.00 (1.58-10.00)

3.67 (1.56-8.31)

7.75 (1.65-14.25)

3.13 (1.44-10.75)

0.645

 Bio-naïve

40 (57.14)

20 (66.67)

2 (10.00)

18 (90.00)

< 0.001

 1

15 (21.43)

7 (23.33)

6 (30.00)

2 (10.00)

 2

8 (11.43)

2 (6.67)

6 (30.00)

0 (0.00)

 3

3 (4.29)

0 (0.00)

3 (15.00)

0 (0.00)

 4

3 (4.29)

1 (3.33)

2 (10.00)

0 (0.00)

 5

1 (1.43)

0 (0.00)

1 (5.00)

0 (0.00)

Concomitant csDMARD

22 (31.43)

13 (43.33)

9 (45.00)

0 (0.00)

0.016

 DAPSA

29.20 (21.80-39.90)

27.90 (21.85-39.73)

36.70 (26.00-47.45)

27.55 (20.50-36.83)

0.187

 PASI

1.20 (0.00-3.30)

1.50 (0.30-3.40)

0.08 (0.00-2.83)

0.95 (0.00-2.93)

0.570

 PsA without psoriasis

22 (31.43)

8 (26.67)

8 (40.00)

6 (30.00)

0.469

 Dactylitis

16 (22.86)

6 (20.00)

6 (30.00)

4 (20.00)

0.869

 Enthesitis

54 (77.14)

24 (80.00)

16 (80.00)

14 (70.00)

0.553

 Nail psoriasis

43 (61.43)

19 (63.33)

10 (50.00)

14 (70.00)

0.383

 CD8+ T cells, %

19.98 (15.12-25.27)

21.02 (18.63-25.76)

18.51 (13.14-23.44)

17.70 (14.96-23.11)

0.086

 Th1 cells, %

1.79 (1.28-2.96)

1.79 (1.50-3.43)

2.25 (1.48-2.94)

1.44 (1.05-2.47)

0.239

 Th17 cells, %

3.32 (2.40-4.61)

3.25 (2.45-4.50)

3.73 (3.09-5.03)

2.81 (2.29-3.36)

0.089

 nTregs, %

1.21 (0.87-1.48)

1.22 (0.98-1.56)

1.13 (0.78-1.50)

1.24 (0.82-1.44)

0.773

 uamTregs, %

1.13 (0.89-1.50)

1.13 (0.95-1.42)

1.23 (0.86-1.62)

1.07 (0.79-1.56)

0.942

 amTregs, %

0.38 (0.22-0.57)

0.36 (0.23-0.58)

0.51 (0.21-0.63)

0.36 (0.25-0.49)

0.760

 Dendritic cells, %

1.21 (0.76-1.82)

1.30 (0.77-1.59)

1.18 (0.79-1.86)

1.10 (0.72-2.18)

0.900

 NK cells, %

7.42 (5.04-9.69)

6.87 (5.16-9.18)

5.80 (4.00-8.69)

9.14 (6.07-11.41)

0.186

 Monocytes, %

3.79 (2.08-5.41)

3.66 (2.03-4.85)

3.50 (2.11-5.13)

4.03 (3.41-8.13)

0.352